CA2495879C - Selective d1/d5 receptor antagonists for the treatment of obesity and cns disorders - Google Patents
Selective d1/d5 receptor antagonists for the treatment of obesity and cns disorders Download PDFInfo
- Publication number
- CA2495879C CA2495879C CA2495879A CA2495879A CA2495879C CA 2495879 C CA2495879 C CA 2495879C CA 2495879 A CA2495879 A CA 2495879A CA 2495879 A CA2495879 A CA 2495879A CA 2495879 C CA2495879 C CA 2495879C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- alkyl
- hydrogen
- aryl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40685602P | 2002-08-29 | 2002-08-29 | |
| US60/406,856 | 2002-08-29 | ||
| PCT/US2003/026878 WO2004020442A1 (en) | 2002-08-29 | 2003-08-27 | Selective d1/d5 receptor antagonists for the treatment of obesity and cns disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2495879A1 CA2495879A1 (en) | 2004-03-11 |
| CA2495879C true CA2495879C (en) | 2011-04-26 |
Family
ID=31978370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2495879A Expired - Fee Related CA2495879C (en) | 2002-08-29 | 2003-08-27 | Selective d1/d5 receptor antagonists for the treatment of obesity and cns disorders |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7211574B2 (enExample) |
| EP (1) | EP1537115B1 (enExample) |
| JP (1) | JP4555685B2 (enExample) |
| CN (1) | CN1688584A (enExample) |
| AT (1) | ATE396996T1 (enExample) |
| AU (1) | AU2003262926A1 (enExample) |
| CA (1) | CA2495879C (enExample) |
| DE (1) | DE60321354D1 (enExample) |
| ES (1) | ES2308016T3 (enExample) |
| MX (1) | MXPA05002249A (enExample) |
| WO (1) | WO2004020442A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1823059A (zh) * | 2003-05-22 | 2006-08-23 | 先灵公司 | 作为治疗肥胖和CNS疾病的选择性D<sub>1</sub>/D<sub>5</sub>受体拮抗剂的5－H－苯并[D]萘并[2,1－B]氮杂䓬衍生物 |
| WO2025194153A1 (en) | 2024-03-15 | 2025-09-18 | Emalex Biosciences, Inc. | Pharmaceutical dosage forms and methods of use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4973586A (en) * | 1986-01-16 | 1990-11-27 | Schering Corporation | Fused benzazepines, compositions of, and medical use thereof |
| WO1987004430A2 (en) * | 1986-01-16 | 1987-07-30 | Schering Corporation | Fused benzazepines |
| ATE78467T1 (de) * | 1987-07-15 | 1992-08-15 | Schering Corp | Kondensierte benzazepine. |
| DK325188D0 (da) * | 1988-06-15 | 1988-06-15 | Novo Industri As | Hidtil ukendte benzazepinderivater |
| WO2003006466A1 (en) * | 2001-07-13 | 2003-01-23 | Pharmacia & Upjohn Company | Hexahydroazepino (4, 5-g) indoles and indolines as 5-ht receptor ligands |
-
2003
- 2003-08-27 MX MXPA05002249A patent/MXPA05002249A/es active IP Right Grant
- 2003-08-27 DE DE60321354T patent/DE60321354D1/de not_active Expired - Lifetime
- 2003-08-27 US US10/649,495 patent/US7211574B2/en not_active Expired - Fee Related
- 2003-08-27 AT AT03791865T patent/ATE396996T1/de not_active IP Right Cessation
- 2003-08-27 AU AU2003262926A patent/AU2003262926A1/en not_active Abandoned
- 2003-08-27 JP JP2004531584A patent/JP4555685B2/ja not_active Expired - Fee Related
- 2003-08-27 ES ES03791865T patent/ES2308016T3/es not_active Expired - Lifetime
- 2003-08-27 WO PCT/US2003/026878 patent/WO2004020442A1/en not_active Ceased
- 2003-08-27 CN CNA038243857A patent/CN1688584A/zh active Pending
- 2003-08-27 CA CA2495879A patent/CA2495879C/en not_active Expired - Fee Related
- 2003-08-27 EP EP03791865A patent/EP1537115B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP4555685B2 (ja) | 2010-10-06 |
| AU2003262926A1 (en) | 2004-03-19 |
| JP2006501244A (ja) | 2006-01-12 |
| CN1688584A (zh) | 2005-10-26 |
| DE60321354D1 (de) | 2008-07-10 |
| CA2495879A1 (en) | 2004-03-11 |
| US7211574B2 (en) | 2007-05-01 |
| US20040058906A1 (en) | 2004-03-25 |
| WO2004020442A1 (en) | 2004-03-11 |
| ES2308016T3 (es) | 2008-12-01 |
| MXPA05002249A (es) | 2005-06-08 |
| EP1537115A1 (en) | 2005-06-08 |
| EP1537115B1 (en) | 2008-05-28 |
| ATE396996T1 (de) | 2008-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4643141B2 (ja) | 肥満治療用のｍｃｈアンタゴニスト | |
| AU2002337956A1 (en) | MCH Antagonists for the treatment of obesity | |
| KR20080089494A (ko) | 화합물 | |
| JP2011006469A (ja) | 肥満および関連障害の処置のための選択的メラニン濃縮ホルモンレセプターアンタゴニストとしての二環式化合物 | |
| WO2009068320A1 (en) | Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 | |
| EP3390374A1 (en) | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels | |
| JP2010047618A (ja) | 肥満症および関連障害の処置のための、選択的メラニン凝集ホルモンレセプターアンタゴニストとしての２置換ベンズイミダゾール誘導体。 | |
| HUP0003118A2 (hu) | 2,7-Szubsztituált oktahidro-1H-pirido-[1,2-a]pirazin-származékok alkalmazása gyógyszerkészítmények előállítására | |
| CA2495879C (en) | Selective d1/d5 receptor antagonists for the treatment of obesity and cns disorders | |
| WO2005035504A2 (en) | 5-h -benzo [d] naphth [2, 1-b] azepine derivative as selective d1/d5 receptor antagonists for the treatment of obesity and cns disorders | |
| JP2006526021A5 (enExample) | ||
| US7423149B2 (en) | Substituted n-aryl amidines as selective D1 dopamine receptor antagonists for the treatment of obesity and CNS disorders | |
| JP2006501244A5 (enExample) | ||
| ES2327763T3 (es) | Heterociclilos utilizados como antagonistas del receptor de la hormona concentrada de melanina para el tratamiento de la obesidad y trastornos relacionados. | |
| JP2010536919A (ja) | ノルエピネフリン、セロトニンまたはドーパミン再取り込み阻害剤として有用な３−アザビシクロ（４．１．０）ヘプタン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |
|
| MKLA | Lapsed |
Effective date: 20130827 |